docarpamine

Docarpamine is an orally active prodrug of dopamine developed for the treatment of refractory ascites in patients with cirrhosis and decompensated chronic liver disease. It is metabolized to dopamine in the body, leading to increased renal blood flow, glomerular filtration rate, and sodium excretion. These effects help manage fluid accumulation (ascites) by leveraging neurohumoral mechanisms. Clinical studies have shown that docarpamine can significantly reduce ascites volume and decrease the frequency of large-volume paracentesis procedures in affected patients. The drug has demonstrated a favorable safety profile in clinical trials[7][10].

Brand names

TanadopaCIQUAAX

Other names

docarpamineDocarpaminaDocarpaminum